INNOGEN-B (02591) announced its financial results for the year ended December 31, 2025. The group reported revenue of approximately 131.5 million yuan, primarily generated from the sales of Isupaglutide α in China. The company recorded a net loss of 341 million yuan, representing a significant increase of 95.4% compared to the previous year. The basic loss per share was 0.79 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments